PF-07921585 / Pfizer - LARVOL DELTA

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: Pfizer | Active, not recruiting ➔ Terminated; The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns

Trial termination • Bladder Cancer • Colorectal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

PD-1 targeting increases the tolerance of IL-12 while maintaining potent anti-tumor immunity (AACR 2025) - "This latter effect was most striking as many published studies suggest PDx therapies only elicit efficacy by affecting the least dysfunctional exhausted T cell subsets, stem-like/progenitor cells. In summary, these data suggest that PF-07921585 may be better tolerated than other IL-12 therapies and has potential to deliver efficacy in PDx-refractory patients by heightening the effector function of CD8 T cell subsets not previously achieved by existing PDx therapies."

Oncology • CD8 • IFNG • IL12A

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (clinicaltrials.gov) - P1 | N=4 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=190 ➔ 4 | Trial completion date: Jan 2029 ➔ Oct 2025 | Trial primary completion date: Jan 2028 ➔ Oct 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Bladder Cancer • Colorectal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (clinicaltrials.gov) - P1 | N=190 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Bladder Cancer • Colorectal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor